Table 3.
Univariate analysis of factors associated with LRR.
| Variables | N | LRR rate, % | P-value | |
|---|---|---|---|---|
| 73 | 12.0 | |||
| Age at diagnosis, years | ≤40 | 39 | 15.4 | 0.030 |
| >40 | 34 | 9.6 | ||
| Clinical T stage | cT1 | 4 | 10.5 | 0.530 |
| cT2 | 47 | 13.2 | ||
| cT3-4 | 22 | 10.2 | ||
| Clinical N stage | cN0 | 22 | 10.4 | 0.669 |
| cN1 | 40 | 12.8 | ||
| cN2-3 | 11 | 13.1 | ||
| Pathological T stage | ypT0/ypTis | 4 | 4.6 | 0.045 |
| ypT1 | 33 | 15.2 | ||
| ypT2 | 29 | 13.2 | ||
| ypT3 | 7 | 8.2 | ||
| Pathological nodal status | ypN- | 25 | 8.7 | 0.019 |
| ypN+ | 48 | 14.9 | ||
| Molecular subtype | HR+/HER2- | 35 | 10.8 | 0.362 |
| HR+/HER2+ | 17 | 10.7 | ||
| HR-/HER2+ | 11 | 17.2 | ||
| TN | 10 | 15.9 | ||
| pCR | Yes | 3 | 3.8 | 0.015 |
| No | 70 | 13.2 | ||
| Pathological MF/MC | Yes | 30 | 14.6 | 0.162 |
| No | 43 | 10.7 | ||
| Tumor grade | 1, 2 | 45 | 10.0 | 0.010 |
| 3 | 28 | 17.7 | ||
| LVI | Yes | 40 | 17.6 | 0.001 |
| No | 33 | 8.6 | ||
| Extensive intraductal component | Yes | 22 | 12.9 | 0.652 |
| No | 51 | 11.6 | ||
| Post-NACT Ki67 | <10% | 24 | 8.5 | 0.001 |
| ≥10% | 47 | 18.4 | ||
| Unknown | 2 | NA | ||
| Mastectomy type | NSM | 46 | 12.4 | 0.674 |
| SSM | 27 | 11.3 | ||
| Axillary surgery | SLNB alone | 37 | 10.3 | 0.126 |
| ALND | 36 | 14.4 | ||
| Adjuvant radiotherapy | Yes | 31 | 9.8 | 0.086 |
| No | 42 | 14.3 | ||
| Adjuvant hormonal therapy | Yes | 52 | 10.8 | 0.076 |
| No | 21 | 16.5 | ||
| Adjuvant chemotherapy | Yes | 10 | 14.3 | 0.529 |
| No | 63 | 11.7 | ||
| Trastuzumab in HER2+ | Yes | 28 | 12.6 | 1.000 |
| No | 0 | 0.0 | ||
| Reconstructive surgery | Autologous flaps | 50 | 11.9 | 0.926 |
| Implants | 23 | 12.2 |
ALND, axillary lymph node dissection; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LRR, locoregional recurrence; LVI, lymphovascular invasion; MF/MC, multifocality/multicentricity; NA, not applicable; NACT, neoadjuvant chemotherapy; NSM, nipple-sparing mastectomy; pCR, pathological complete response; SLNB, sentinel lymph node biopsy; SSM, skin-sparing mastectomy; TN, triple negative.